logo-loader
viewAnteris Technologies Ltd

Anteris Technologies hosting key opinion leader symposium to update on TAVR R&D program and ADAPT trial

The structural heart company will update on its TAVR R&D program and the ongoing first-in-human trial of its ADAPT® 3D single-piece aortic valve for Surgical Aortic Valve Replacement procedures.

Anteris Technologies Ltd -
Anteris Technologies is a structural heart company advancing the DurAVRTM valve, a novel aortic valve replacement solution

Anteris Technologies Ltd (ASX:AVR) (FRA:DDF) will host a key opinion leader symposium on the use of transcatheter aortic valve replacement (TAVR) on July 21, 2020, at 1:00am AEST (July 20 at 11:00 am USA EDT).

During the symposium to be moderated by Credit Suisse, the company will update on its TAVR research & development program, as well as on the ongoing first-in-human trial of its ADAPT® 3D single-piece aortic valve for Surgical Aortic Valve Replacement (SAVR) procedures.

The symposium, entitled 'Next Generation Technologies for the era of TAVR in Younger Low-Risk Patients with Aortic Stenosis', will provide investors and analysts with a comprehensive profile of current trends in the use of TAVR and the future of this technology to treat younger, low-risk patients with aortic stenosis.

It will address how current TAVR solutions are suitable for this newly approved patient demographic, what challenges they have, and what are the leading next-generation technologies that are in development.

Key opinion leaders

The forum will be moderated by Matt Miksic, senior analyst at Credit Suisse, and will feature the following key opinion leaders:

➢ Dr Samir Kapadia, MD (Cleveland Clinic, Cleveland, Ohio)

➢ Dr Michael Reardon, MD (Houston Methodist, Houston, Texas)

➢ Dr Paul Sorajja, MD (Minneapolis Heart Institute Foundation, Minneapolis, Minnesota)

Registration for the event can be done at https://bit.ly/38CGeDA

A recording will be available after the event.

Anteris Technologies is a structural heart company advancing the DurAVRTM valve, a novel aortic valve replacement solution. Its ADAPT® tissue platform, a next-generation technology with zero DNA and zero glutaraldehyde, is the only bioscaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery.

Its best-in-class ADAPT® tissue combined with its valve design has the potential to solve the problems associated with current aortic valve replacement options which are durability and preventing valve degradation.

Quick facts: Anteris Technologies Ltd

Price: 3.8 AUD

ASX:AVR
Market: ASX
Market Cap: $22.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

on 6/7/20

2 min read